Adenoviral-mediated gene therapy for cardiovascular conditions
Executive Summary
National Heart, Lung & Blood Institute is seeking capability statements from parties interested in entering into a Cooperative Research & Development Agreement to develop adenoviral-mediated gene therapy approaches to treating two conditions: restenosis after angioplasty and stimulation of collateral formation in the myocardium. Capability statements are due on or before June 16, according to May 17 Federal Register and should be submitted to Mary Jude Jacobs, NHLBI, 9000 Rockville Pike, Building 31, Room 5A48, Bethesda, Md. 20892